

- carcinomas and normal tissues determined by a quantitative radioligand binding assay, *Analytical biochemistry* 2005, 338:284-293
- [0117] 45. Weitman S D, Lark R H, Coney L R, Fort D W, Frasca V, Zurawski V R, Jr., Kamen B A: Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues, *Cancer research* 1992, 52:3396-3401
- [0118] 46. Kane M A, Elwood P C, Portillo R M, Antony A C, Najfeld V, Finley A, Waxman S, Kolhouse J F: Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells, *The Journal of clinical investigation* 1988, 81:1398-1406
- [0119] 47. Cho B K, Roy E J, Patrick T A, Kranz D M: Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells, *Bioconjugate chemistry* 1997, 8:338-346
- [0120] 48. Speyer C L, Gao H, Rancilio N J, Neff T A, Huffnagle G B, Sarma J V, Ward P A: Novel chemokine responsiveness and mobilization of neutrophils during sepsis, *The American journal of pathology* 2004, 165: 2187-2196
- [0121] 49. Ethier S P, Mahacek M L, Gullick W J, Frank T S, Weber B L: Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media, *Cancer research* 1993, 53:627-635
- [0122] 50. Tran T, Shatnawi A, Zheng X, Kelley K M, Ratnam M: Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting, *Cancer research* 2005, 65:4431-4441
- [0123] 51. Iking-Konert C, Vogt S, Radsak M, Wagner C, Hansch G M, Andrassy K: Polymorphonuclear neutrophils in Wegener's granulomatosis acquire characteristics of antigen presenting cells, *Kidney Int* 2001, 60:2247-2262
- [0124] 52. van Egmond M, van Vuuren A J, Morton H C, van Spriel A B, Shen L, Hofhuis F M, Saito T, Mayadas T N, Verbeek J S, van de Winkel J G: Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18), *Blood* 1999, 93:4387-4394
- [0125] 53. Weisbart R H, Kacena A, Schuh A, Golde D W: G M-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism, *Nature* 1988, 332:647-648
- [0126] 54. Morton H C, van Egmond M, van de Winkel J G: Structure and function of human IgA Fc receptors (Fc alpha R), *Critical reviews in immunology* 1996, 16:423-440
- [0127] 55. Monteiro R C, Van De Winkel J G: IgA Fc receptors, *Annu Rev Immunol* 2003, 21:177-204
- [0128] 56. Reljic R: In search of the elusive mouse macrophage Fc-alpha receptor, *Immunol Lett* 2006, 107:80-81
- [0129] 57. Prabakaran M, Grailer J J, Pilla S, Steeber D A, Gong S: Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery, *Biomaterials* 2009, 30:6065-6075
- [0130] 58. Prabakaran M, Grailer J J, Pilla S, Steeber D A, Gong S: Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn H40, poly(L-lactide) and poly(ethylene glycol) for tumor-targeted drug delivery, *Biomaterials* 2009, 30:3009-3019
- [0131] 59. Prabakaran M, Grailer J J, Steeber D A, Gong S: Thermosensitive micelles based on folate-conjugated poly(N-vinylcaprolactam)-block-poly(ethylene glycol) for tumor-targeted drug delivery, *Macromolecular bioscience* 2009, 9:744-753
- [0132] 60. Li H, Lu Y, Piao L, Wu J, Yang X, Kondadasula S V, Carson W E, Lee R J: Folate-immunoglobulin G as an anticancer therapeutic antibody, *Bioconjugate chemistry* 2010, 21:961-968
- [0133] 61. Speyer C L, Smith J S, Banda M, DeVries J A, Mekani T, Gorski D H: Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer, *Breast cancer research and treatment* 2012, 132: 565-573
- What is claimed is:
1. A complex comprising:
a folate receptor alpha (FRA)-expressing cancer cell from a subject; and
bound thereto, a conjugate comprising:
an Fc portion of an IgA antibody, wherein said Fc portion comprises a CH2 domain and a CH3 domain but does not comprise a hinge region; and
folate or a folate analog.
 2. The complex of claim 1, wherein the conjugate further comprises a linker.
 3. The complex of claim 2, wherein the linker is a peptide linker.
 4. The complex of claim 2, wherein the linker is a non-peptide linker.
 5. The complex of claim 1, wherein the Fc portion is a variant Fc.
 6. The complex of claim 1, wherein the Fc portion is a variant Fc and the conjugate comprises folate.
 7. The complex of claim 1, wherein the Fc portion is a variant Fc and the conjugate comprises a folate analog.
 8. The complex of claim 1, wherein the Fc fragment consists of a CH2/CH3 region from an IgA antibody.
 9. The complex of claim 1, which is in vitro, or in vivo in the subject.
 10. A method of inducing antibody-dependent cell-mediated cytotoxicity (ADCC), against folate receptor alpha (FRA)-expressing cancer cells, in neutrophils in a subject, the method comprising:
administering to the subject a therapeutically effective amount of a conjugate comprising:
an Fc portion of an IgA antibody, wherein said Fc portion comprises a CH2 domain and a CH3 domain but does not comprise a hinge region; and
folate or a folate analog,
thereby triggering ADCC, against FRA-expressing cancer cells, in neutrophils in the subject.
 11. The method of claim 10, wherein the cancer cells are breast cancer, ovarian cancer, or lung cancer cells.
 12. The method of claim 10, wherein the cancer cells are triple negative breast cancer cells.
 13. The method of claim 10, wherein the cancer cells that lack receptors for one or more of estrogen, progesterone and epithelial growth factor.
 14. The method of claim 10, wherein administration is by intravenous administration.
 15. The method of claim 10, wherein the conjugate is formulated for intravenous administration.